Outcome of Board Meeting
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts more than Nifty Smallcap 250 and 1.2 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indegene Limited reported audited consolidated financial results for FY2026 with revenue from operations growing 23.6% to Rs. 35,105 million from Rs. 28,393 million in FY2025. However, profit after tax declined marginally to Rs. 4,011 million from Rs. 4,067 million, impacted by Rs. 203 million in exceptional litigation provisions (TCPA lawsuit settlement). The Board recommended a final dividend of Rs. 2.25 per equity share. During the year, the company completed four acquisitions including BioPharm Parent Holdings for Rs. 8,821 million, significantly expanding its goodwill to Rs. 11,343 million. Deloitte Haskins & Sells issued an unmodified (clean) audit opinion. A contingent liability of Rs. 1,114 million exists due to a transfer pricing draft order under MAP resolution.
Revenue growth of 23.6% demonstrates strong business expansion driven by acquisitions, though PAT remained flat due to exceptional items and integration costs. The clean audit opinion and dividend recommendation are positive signals for shareholders despite margin compression.